• Something wrong with this record ?

Context-dependent multifunctionality of galectin-1: a challenge for defining the lectin as therapeutic target

K. Smetana, S. André, H. Kaltner, J. Kopitz, HJ. Gabius,

. 2013 ; 17 (4) : 379-92.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

INTRODUCTION: One route of translating the information encoded in the glycan chains of cellular glycoconjugates into physiological effects is via receptor (lectin) binding. A family of endogenous lectins, sharing folding, a distinct sequence signature and affinity for β-galactosides (thus termed galectins), does so effectively in a context-dependent manner. AREAS COVERED: An overview is given on the multifunctional nature of galectins, with emphasis on galectin-1. The broad range of functions includes vital processes such as adhesion via glycan bridging, glycoconjugate transport or triggering signaling relevant, for example, for growth regulation. Besides distinct glycoconjugates, this lectin can also interact with certain proteins so that it can target counterreceptors at all sites of location, that is, in the cytoplasm and/or nucleus, at both sides of the membrane or extracellularly. Approaches to strategically exploit galectin activities with therapeutic intentions are outlined. EXPERT OPINION: The wide versatility of sugar coding and the multifunctionality of galectin-1 explain why considering to turn the protein into a therapeutic target is an ambitious aim. Natural pathways shaped by physiologic master regulators (e.g., the tumor suppressor p16(INK4a)) are suggested to teach inspiring lessons as to how the lectin might be recruited to clinical service.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13031738
003      
CZ-PrNML
005      
20131023103817.0
007      
ta
008      
131002s2013 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1517/14728222.2013.750651 $2 doi
035    __
$a (PubMed)23289445
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Smetana, Karel $u Institute of Anatomy, 1st Faculty of Medicine, Charles University, U Nemocnice 3, 128 00 Prague, Czech Republic.
245    10
$a Context-dependent multifunctionality of galectin-1: a challenge for defining the lectin as therapeutic target / $c K. Smetana, S. André, H. Kaltner, J. Kopitz, HJ. Gabius,
520    9_
$a INTRODUCTION: One route of translating the information encoded in the glycan chains of cellular glycoconjugates into physiological effects is via receptor (lectin) binding. A family of endogenous lectins, sharing folding, a distinct sequence signature and affinity for β-galactosides (thus termed galectins), does so effectively in a context-dependent manner. AREAS COVERED: An overview is given on the multifunctional nature of galectins, with emphasis on galectin-1. The broad range of functions includes vital processes such as adhesion via glycan bridging, glycoconjugate transport or triggering signaling relevant, for example, for growth regulation. Besides distinct glycoconjugates, this lectin can also interact with certain proteins so that it can target counterreceptors at all sites of location, that is, in the cytoplasm and/or nucleus, at both sides of the membrane or extracellularly. Approaches to strategically exploit galectin activities with therapeutic intentions are outlined. EXPERT OPINION: The wide versatility of sugar coding and the multifunctionality of galectin-1 explain why considering to turn the protein into a therapeutic target is an ambitious aim. Natural pathways shaped by physiologic master regulators (e.g., the tumor suppressor p16(INK4a)) are suggested to teach inspiring lessons as to how the lectin might be recruited to clinical service.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a biologický transport $x účinky léků $7 D001692
650    _2
$a buněčná adheze $x účinky léků $7 D002448
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    12
$a racionální návrh léčiv $7 D015195
650    _2
$a galektin 1 $x antagonisté a inhibitory $x metabolismus $7 D037483
650    _2
$a galektiny $x antagonisté a inhibitory $x metabolismus $7 D037161
650    _2
$a glykokonjugáty $x metabolismus $7 D006001
650    _2
$a lidé $7 D006801
650    _2
$a cílená molekulární terapie $7 D058990
650    _2
$a nádorové proteiny $x antagonisté a inhibitory $x metabolismus $7 D009363
650    _2
$a nádory $x farmakoterapie $x prevence a kontrola $7 D009369
650    _2
$a signální transdukce $x účinky léků $7 D015398
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a André, Sabine $u - $7 gn_A_00006374
700    1_
$a Kaltner, Herbert $u -
700    1_
$a Kopitz, Jürgen $u -
700    1_
$a Gabius, Hans-Joachim $u -
773    0_
$w MED00182172 $t Expert opinion on therapeutic targets $x 1744-7631 $g Roč. 17, č. 4 (2013), s. 379-92
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23289445 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20131002 $b ABA008
991    __
$a 20131023104409 $b ABA008
999    __
$a ok $b bmc $g 995825 $s 830183
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 17 $c 4 $d 379-92 $i 1744-7631 $m Expert opinion on therapeutic targets $n Expert Opin Ther Targets $x MED00182172
LZP    __
$a Pubmed-20131002

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...